1. SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer.
- Author
-
Mazur PK, Reynoird N, Khatri P, Jansen PW, Wilkinson AW, Liu S, Barbash O, Van Aller GS, Huddleston M, Dhanak D, Tummino PJ, Kruger RG, Garcia BA, Butte AJ, Vermeulen M, Sage J, and Gozani O
- Subjects
- Adenocarcinoma enzymology, Adenocarcinoma genetics, Adenocarcinoma metabolism, Adenocarcinoma pathology, Adenocarcinoma of Lung, Animals, Cell Line, Tumor, Cell Transformation, Neoplastic genetics, Cell Transformation, Neoplastic pathology, Disease Models, Animal, Humans, Lung Neoplasms enzymology, Lung Neoplasms genetics, Lung Neoplasms metabolism, Lung Neoplasms pathology, MAP Kinase Kinase Kinase 2 chemistry, MAP Kinase Kinase Kinases chemistry, Methylation, Mice, Mitogen-Activated Protein Kinases metabolism, Oncogene Protein p21(ras) genetics, Pancreatic Neoplasms enzymology, Pancreatic Neoplasms genetics, Pancreatic Neoplasms metabolism, Pancreatic Neoplasms pathology, Protein Phosphatase 2 antagonists & inhibitors, Protein Phosphatase 2 metabolism, Proto-Oncogene Proteins A-raf metabolism, Signal Transduction, Cell Transformation, Neoplastic metabolism, Histone-Lysine N-Methyltransferase metabolism, Lysine metabolism, MAP Kinase Kinase Kinase 2 metabolism, MAP Kinase Kinase Kinases metabolism, Oncogene Protein p21(ras) metabolism
- Abstract
Deregulation of lysine methylation signalling has emerged as a common aetiological factor in cancer pathogenesis, with inhibitors of several histone lysine methyltransferases (KMTs) being developed as chemotherapeutics. The largely cytoplasmic KMT SMYD3 (SET and MYND domain containing protein 3) is overexpressed in numerous human tumours. However, the molecular mechanism by which SMYD3 regulates cancer pathways and its relationship to tumorigenesis in vivo are largely unknown. Here we show that methylation of MAP3K2 by SMYD3 increases MAP kinase signalling and promotes the formation of Ras-driven carcinomas. Using mouse models for pancreatic ductal adenocarcinoma and lung adenocarcinoma, we found that abrogating SMYD3 catalytic activity inhibits tumour development in response to oncogenic Ras. We used protein array technology to identify the MAP3K2 kinase as a target of SMYD3. In cancer cell lines, SMYD3-mediated methylation of MAP3K2 at lysine 260 potentiates activation of the Ras/Raf/MEK/ERK signalling module and SMYD3 depletion synergizes with a MEK inhibitor to block Ras-driven tumorigenesis. Finally, the PP2A phosphatase complex, a key negative regulator of the MAP kinase pathway, binds to MAP3K2 and this interaction is blocked by methylation. Together, our results elucidate a new role for lysine methylation in integrating cytoplasmic kinase-signalling cascades and establish a pivotal role for SMYD3 in the regulation of oncogenic Ras signalling.
- Published
- 2014
- Full Text
- View/download PDF